The search for CJC-1295 in Johi inevitably reaches the same conclusion: research peptides are supplied via specialist online vendors, not local retail. This concentration of supply in online vendors is a genuine benefit for researchers — top vendors distinguish themselves through rigorous testing in ways no local retailer can match. Vendors worth sourcing from openly share batch-matched Certificates of Analysis containing HPLC purity data, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the exact batch you are purchasing. What follows is a vendor evaluation and quality guide built specifically around CJC-1295, covering everything a Johi researcher needs to source confidently.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Johi comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
The first step for any Johi researcher sourcing CJC-1295 is identifying 2-3 vendors with documented positive community reputations — search results alone are too heavily influenced by marketing spend. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. Strong quality indicators beyond COA quality: documented vendor history spanning multiple years, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. The lyophilised (freeze-dried) form of CJC-1295 is far superior to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations break down rapidly even under refrigeration.
Order CJC-1295 — ships to Johi
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means the safety evidence is drawn from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg vial with 2mL bac water yields 2.5mg/mL — equivalent to 25mcg per unit on an insulin syringe. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger dangerous immune responses at minute levels, and no pricing advantage justifies skipping this verification. Protocol documentation — keeping clear records of compound, timing, and method — is a research best practice for CJC-1295 that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
